ARFGAP1

ADP-ribosylation factor GTPase-activating protein 1 · Q8N6T3 · ARFGAP1 on Sugi Atlas →

9 patent compounds predicted against ARFGAP1, 8 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1056416 SCHEMBL1056416 1.00 1/20
SCHEMBL1056417 SCHEMBL1056417 1.00 1/20
SCHEMBL29358731 SCHEMBL29358731 1.00 1/20
SCHEMBL30753542 SCHEMBL30753542 1.00 1/20
Water Water (SCHEMBL29794967) 0.98 1/20
SCHEMBL28800958 SCHEMBL28800958 0.55 1/20
SCHEMBL28800959 SCHEMBL28800959 0.55 1/20
SCHEMBL24421960 SCHEMBL24421960 0.44 1/20

Clinical trials — most relevant to ARFGAP1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa PHASE3ACTIVE_NOT_RECRUITING
Safety and Efficacy of AAV9/AP4B1 (BFB-101) For Patients With AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47) PHASE1/PHASE2NOT_YET_RECRUITING
Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt) PHASE1/PHASE2RECRUITING
Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC) PHASE2COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer PHASE2COMPLETED
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma PHASE1/PHASE2RECRUITING
Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1 PHASE2COMPLETED
68 Gallium-Fibroblast Activating Protein Inhibitors-46 Positron Emission Tomography - Computerized Tomography for Molecular Assessment of Fibroblast Activation and Risk Assessment in Solid Tumors PHASE2UNKNOWN
Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1 PHASE2COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Interleukin-2 Treatment for Wiskott-Aldrich Syndrome PHASE1COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
Prospective Validation of a DNA Damage Repair-Hippo Pathway Signature in Patients With Advanced Gastric Cancer nanUNKNOWN
Study of the Pathophysiological Mechanisms Involved in Bleeding Events nanCOMPLETED
ADRB3, ROCK2 and GEF Levels in Overactive Bladder Patients nanCOMPLETED
Study of Proteins in Head and Neck Cancer Cells nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED
Value of MicroRNA30a in Philadelphia Positive Leukemic Patients nanUNKNOWN
Sexually Dimorphic Effects of GHRH in Adult Growth Hormone Testing nanCOMPLETED
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA nanRECRUITING
Genetic Characterization of Parkinson's Disease nanCOMPLETED
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia nanRECRUITING
Towards an Easy-to-use Adrenal Cancer/Tumor Identity Card nanCOMPLETED
Investigating the Genetic Basis of Pseudoexfoliation Syndrome, Angle-closure Glaucoma and Primary Open-angle Glaucoma nanRECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Characterization of Microbiological and Genetic Features in Prostate Cancer and Their Association with Disease Stage nanENROLLING_BY_INVITATION
Genetic Analysis of Gray Platelet Syndrome nanCOMPLETED
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial nanRECRUITING
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a ARFGAP1 binder may also engage these)

ProteinNameSimilarity
Q9EPJ9 1.000 Q9EPJ9 →
Q62848 1.000 Q62848 →
O80925 0.999 O80925 →
Q9M354 0.996 Q9M354 →
Q8N6H7 0.992 Q8N6H7 →
Q4R4C9 0.991 Q4R4C9 →
Q3MID3 0.990 Q3MID3 →
Q99K28 0.990 Q99K28 →
P35197 0.990 P35197 →
Q8CHU3 0.989 Q8CHU3 →
O82171 0.989 O82171 →
Q9FL69 0.989 Q9FL69 →
Q9FIQ0 0.989 Q9FIQ0 →
Q8H100 0.988 Q8H100 →
Q5R787 0.987 Q5R787 →
O94601 0.987 O94601 →
Q9Z1Z3 0.987 Q9Z1Z3 →
Q17R07 0.987 Q17R07 →
A1L520 0.987 A1L520 →
Q9D8S3 0.986 Q9D8S3 →
Q6NYG6 0.986 Q6NYG6 →
A5E032 0.985 A5E032 →
Q9LT75 0.985 Q9LT75 →
Q9NP61 0.984 Q9NP61 →
Q28CM8 0.984 Q28CM8 →
Q149L6 0.984 Q149L6 →
P53604 0.984 P53604 →
O13633 0.984 O13633 →
Q6E3D4 0.984 Q6E3D4 →
Q5RAT7 0.984 Q5RAT7 →